You are here

Article Text

Article menu
Download PDFPDF
Scientific letters
Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial
  1. W J R Desmet1,
  2. J Dens1,
  3. P Coussement2,
  4. F Van de Werf1
  1. 1Department of Cardiology, UH Gasthuisberg, Leuven, Belgium
  2. 2AZ Sint-Jan AV, Department of Cardiology, Brugge, Belgium
  1. Correspondence to:
    Walter JR Desmet, Department of Cardiology, UH Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium;
    Walter.Desmet{at}uz.kuleuven.ac.be

https://doi.org/10.1136/heart.88.3.293

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    After successful percutaneous coronary intervention (PCI), 24–44% of patients suffer some myocardial damage as indicated by a significant change in the concentrations of cardiospecific troponin or the MB isoenzyme of creatine kinase (CK-MB).1,2 Patients with minor increases of these cardiac markers after PCI constitute a population with a worse long term prognosis.3 Preconditioning of human myocardium can be obtained by intracoronary administration of adenosine, as indicated by attenuation of ischaemia and chest pain in patients undergoing PCI.4 In the present trial (ADELINE, does ADEnosine Limit myocardial Necrosis), we investigated the effect of intracoronary administration on chest pain and ischaemia during a 90 second balloon inflation during PCI. In addition, we evaluated the release of cardiac markers after angiographically successful coronary intervention.

    METHODS

    Patients were eligible when a PCI was planned of a lesion in a primary or secondary branch of either coronary artery, supplying a sizeable area of myocardium.

    Exclusion criteria were: myocardial infarction during the previous two weeks; use of theophylline preparations, dipyridamole or glibenclamide; bronchial asthma; second or third degree atrioventricular block, and recanalisation of a total occlusion. This study was approved by the institutional review board, and written informed consent was obtained from all patients.

    In this single centre, single blind study, 32 patients were randomly allocated to a control or an adenosine treated group. One patient was excluded because of occlusion of a major branch during PCI, and three patients were excluded because …

    View Full Text